Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent

Journal of the National Cancer Institute

Volumn 83, Issue 20, 1991, Pages 1488-1491

  Jordan, V Craig ^a   Fritz, Nancy F ^a   Langan Fahey, Susan ^a   Thompson, Mark ^a   Tormey, Douglass C ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER PREVENTION; CLINICAL ARTICLE; FEMALE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; MENSTRUATION; OVULATION; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGENS; FEMALE; GONADOTROPINS, PITUITARY; HUMAN; MASTECTOMY; MENOPAUSE; MIDDLE AGE; PROGESTERONE; RADIOIMMUNOASSAY; SEX HORMONE-BINDING GLOBULIN; SEX HORMONES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; TIME FACTORS;

EID: 0025936010     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/83.20.1488     Document Type: Article

References (34)

1. COLE MP, JONES CT, TODD ID: A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25:270-275, 1971
2. WARD HW: Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. Br Med J 1:13-14, 1973
3. TORMEY DC, SIMON RM, LIPPMAN ME, ET AL: Evaluation of tamoxifen dose in advanced breast cancer. A progress report. Cancer Treat Rep 60:1451-1459, 1976
4. MANNI A, PEARSON OH: Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: Effects on ovarian function. Cancer Treat Rep 64:779-785, 1980
5. INGLE JN, KROOK JE, GREEN SJ, ET AL: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178-185, 1986
6. BUCHANAN RB, BLAMEY RW, DURRANT KR, ET AL: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326-1330, 1986
7. SAWKA CA, PRITCHARD KI, PATERSON DJ, ET AL: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 46:3152-3156, 1986
8. JORDAN VC, MURPHY CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11:578-610, 1990
9. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
10. JORDAN VC: Long-term adjuvant therapy for breast cancer. In Important Advances in Oncology (DeVita VT Jr, Hellman S, Rosenberg SA, eds). Philadelphia: Lippincott, 1989, pp 179-192
11. TORMEY DC, JORDAN VC: Long-term tamoxifen adjuvant therapy in node-positive breast cancer: A metabolic and pilot clinical study. Breast Cancer Res Treat 4:297-302, 1984
12. DELOZIER T, JULIEN JP, JURET P, ET AL: Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial. Breast Cancer Res Treat 7:105-109, 1986
13. FISHER B, BROWN A, WOLMARK N, ET AL: Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 106:649-654, 1987
14. BREAST CANCER TRIALS COMMITTEE, SCOTTISH TRIALS OFFICE (MRC), EDINBURGH: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 2:171-175, 1987
15. NOLVADEX ADJUVANT TRIAL ORGANISATION: Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Lancet 1:836-840, 1985
16. CRC ADJUVANT BREAST TRIAL WORKING PARTY: Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 57:604-607, 1988
17. FISHER B, COSTANTINO J, REDMOND C, ET AL: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
18. POWLES TJ, TILLYER CR, JONES AL, ET AL: Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 26:680-684, 1990
19. GROOM GV, GRIFFITHS K: Effect of antioestrogen tamoxifen on plasma levels of lutemizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70:421-428, 1976
20. SENIOR BE, CAWOOD ML, OAKLEY RE, ET AL: A comparison of the effects of clomiphene and tamoxifen treatment on the concentrations of oestradiol and progesterone in the peripheral plasma of infertile women. Clin Endocrinol 1978:381-389, 1978
21. SHERMAN BM, CHAPLER FK, CRICKARD K, ET AL: Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64:398-404, 1979
22. ROSE DP, DAVIS TE: Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 40:4043-4047, 1980
23. DNISTRIAN AM, GREENBERO EJ, DILLON HJ, ET AL: Chemohormonal therapy and endocrine function in breast cancer patients. Cancer 56:63-70, 1985
24. JORDAN VC, FRITZ NF, TORMEY DC: Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on nodepositive patients with breast cancer. Cancer Res 47:624-630, 1987
25. RAVDIN PM, FRITZ NF, TORMEY DC, ET AL: Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48:1026-1029, 1988
26. JORDAN VC, FRITZ NF, TORMEY DC: Longterm adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III. Cancer Res 47:4517-4519, 1987
27. LANGAN-FAHEY SM, TORMEY DC, JORDAN VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26:883-888, 1990
28. GERHARD I, RUNNEBAUM B: Comparison between tamoxifen and clomiphene therapy in women with anovulation. Arch Gynecol 227:279-288, 1979
29. RUIZ-VELASCO V, ROSAS-ARCEO J, MATUTE MM: Clinical inducers of ovulation: Comparative results. Int J Fertil 24:61-64, 1979
30. FORNANDER T, RUTQVIST LE, CEDERMARK B, ET AL: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1:117-120, 1989
31. PIKE MC, HENDERSON BE, KRAILO MD, ET AL: Breast cancer in young women and use of oral contraceptives: Possible modifying effect of formulation and age at use. Lancet 2:926-929, 1983
32. BERGKVIST L, ADAMI HO, PERSSON I, ET AL: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321:293-297, 1989
33. ROBINSON SP, JORDAN VC: Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 47:5386-5390, 1987
34. MOURIDSEN HT, ELLEMANN K, MATTSSON W, ET AL: Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63:171-175, 1979